Table 2.
Summary of preclinical studies of UMGT for cancer immunotherapy.
| UMGT Approaches | Tumor models | Gene constructs | Ultrasound parameters | Target cell | Ref. |
|---|---|---|---|---|---|
| 5.1 Transfection with ultrasound | Fibrosarcoma, murine models | GM-CSF pDNA | f = 1 MHz, ISATA = 1.0 W/cm2, Duty cycle = 20%, t = 5 min | Tumor cells | [159] |
| Melanoma and renal carcinoma murine models | IL-12 pDNA | f = 200 kHz (laboratory lithotripter similar to Dornier HM-3 lithotripter), PNP = 7.4 MPa, PRF = 2 Hz, Shock Waves = 500 (Duty cycle: 0.5%) + intratumoral air bubbles | Tumor cells | [160] | |
| 5.2 MB-based transfection | Prostate cancer murine models, human prostate tumor xenografts | IL-27 pDNA | f = 1 MHz, PNP = 0.12 MPa, ISATA = 1 W/cm2, PRF = 2 Hz, Duty cycle = 50%, t = 2 min, + SonoVue MBs | Tumor cells | [161] |
| Melanoma murine models | IFN-β pDNA | f = 1.011 MHz, ISATA = 0.22 W/cm2, Duty cycle = 50%, PRF = 0.5 Hz, t = 3 min, + Sonazoid MBs | Tumor cells | [162] | |
| Cervical cancer murine models | miR-34a | f = 1 MHz, I = 1.5 W/cm2, Duty cycle = 50%, t = 90 s, + cationic lipid MBs | Tumor cells | [163] | |
| Breast cancer, murine models | IFN-β pDNA | f = 250 kHz, PNP = 500 kPa, ISPTA = 1 W/cm2, PRF = 30 Hz, t = 3 min, Duty Cycle = 12%, + anti-EpCAM conjugated MBs | Stromal cells, tumor cells | [21] | |
| 5.3 Ultrasound-responsive delivery system | Ovarian carcinoma, murine models | IL-12 pDNA | f = 1 MHz, I = 0.7 W/cm2, t = 60 s, + liposomal bubbles | Cells in TME | [164] |
| Lymphoma murine models | OVA pDNA | f = 2.062 MHz, I = 4 W/cm2, Duty cycle = 50%, t = 20 s, +mannose-modified liposomes | APCs | [165] | |
| Melanoma murine models | pUb-M cDNA | Duty cycle = 50%, PRF = 10 Hz, t = 2 min, +mannose-modified liposomes f = 1.045 MHz, I = 1 W/cm2 (for intravenous injection) f = 2.062 MHz, I = 4 W/cm2 (for intradermal and intrasplenic injection) |
APCs | [166] | |
| 5.4 Modulation of immune cell functionality | Lymphoma and leukemia cell models | Anti-CD19 CAR gene loaded lentiviruses | f = 2 MHz, ISPTA = 0.6 W/cm2, PNP = 0.6 MPa, PRF = 5 Hz, Duty cycle = 5%, t = 10 min, +MBs | Jurkat T cells and PBMCs | [167] |
| Lymphoma and prostate cancer models | Cre-lox gene with HSP promotor | f = 1.5 MHz | T cells | [168] | |
| DCs from bone marrow of C57Bl/6 mice | mRNA encoding luciferase or GFP | f = 1 MHz, I = 2 W/cm2, Duty cycle = 50% t = 30 s, + lipoplexes + MBs | DCs | [169] | |
| Melanoma lung metastasis murine models | Antigen mRNA and TriMix mRNA | f = 1 MHz, ISPTA = 2 W/cm2, PNP = 800 kPa, Duty cycle = 20%, PRF = 100 Hz, t = 30 s, lipid MBs | DCs | [170] | |
| Hepatocellular carcinoma human cells | Foxp3 siRNA | f = 2.5 MHz, MI = 1.4, t = 150 s, + SonoVue MBs | Tregs | [171] |
Abbreviation: f: frequency, I: acoustic intensity (this notation is used when the specific intensity metric cannot be determined), PNP: peak negative pressure, PRF: pulse repetition frequency, MI: mechanical index, EpCAM: Epithelial cell adhesion molecule, IFN-β: Interferon-beta, IL-27: interleukin 27, IL-12: interleukin 12, GM-CSF: granulocyte-macrophage colony-stimulating factor, OVA: ovalbumin, HSP: heat shock protein, Foxp3: Forkhead box P3, APC: antigen-presenting cells, DCs: dendritic cells, PMBCs: peripheral blood mononuclear cells, ISPTA: Spatial peak temporal average intensity, ISATA: Spatial average temporal average intensity